Mehdi Hamadani on Treating NHL in the Community Oncology Setting During the Pandemic

Laura C. Michaelis, MD: In My Experience Question 1

How has the COVID-19 pandemic changed your approach to the selection of tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia?

Recorded A...

Lymphoma

COVID-19

The ASCO Post Staff

Mehdi Hamadani, MD: In My Experience Question 1

Are you testing for COVID-19 before administering therapy on an outpatient basis for patients with non-Hodgkin lymphoma?

Recorded April 21, 2020.

Multiple Myeloma

COVID-19

The ASCO Post Staff

Saad Z. Usmani, MD: In My Experience Question 5

For community oncologists treating patients with multiple myeloma during the COVID-19 pandemic, what resources and clinical pearls would you suggest?

Recorded April 24, 2020.

Leukemia

COVID-19

The ASCO Post Staff

Laura C. Michaelis, MD: In My Experience Question 5

For community oncologists treating patients with chronic myeloid leukemia or chronic lymphocytic leukemia during the COVID-19 pandemic, what resources and clinical pearls would you suggest?

Hematologic Malignancies

COVID-19

The ASCO Post Staff

Miguel-Angel Perales, MD, and Syed A. Abutalib, MD, on Bone Marrow Transplants During the COVID-19 Pandemic

Syed A. Abutalib, MD, of Cancer Treatment Centers of America, talks with Miguel-Angel Perales, MD, of Memorial Sloan Kettering Cancer Center, about the chall...

Mehdi Hamadani, MD: In My Experience Question 5

Related Videos

Laura C. Michaelis, MD: In My Experience Question 1

Mehdi Hamadani, MD: In My Experience Question 1

Saad Z. Usmani, MD: In My Experience Question 5

Laura C. Michaelis, MD: In My Experience Question 5

Miguel-Angel Perales, MD, and Syed A. Abutalib, MD, on Bone Marrow Transplants During the COVID-19 Pandemic

‘Dangling’ Accelerated Approvals of Anti–PD-1/PD-L1 Antibodies to Be Discussed at FDA Oncologic Drugs Advisory Committee Meeting

Meta-analysis of Treatment Modalities for Locally Advanced Head and Neck Cancer

Glofitamab for Relapsed or Refractory B-Cell Lymphoma

Addition of Neoadjuvant FOLFIRINOX to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer

FDA Pipeline Bemarituzumab Granted Breakthrough Therapy Designation for FGFR2b-Overexpressing, HER2-Negative Gastric Cancer